Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 232

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants

Open access
Xu, Jianliang, Xu, Kai, Jung, Seolkyoung, Conte, Andrea, Lieberman, Jenna, Muecksch, Frauke, Lorenzi, Julio Cesar Cetrulo, Park, Solji, Schmidt, Fabian, Wang, Zijun, Huang, Yaoxing, Luo, Yang, Nair, Manoj S., Wang, Pengfei, Schulz, Jonathan E., Tessarollo, Lino, Bylund, Tatsiana, Chuang, Gwo-Yu, Olia, Adam S., Stephens, Tyler, Teng, I-Ting, Tsybovsky, Yaroslav, Zhou, Tongqing, Munster, Vincent, Ho, David D., Hatziioannou, Theodora, Bieniasz, Paul D., Nussenzweig, Michel C., Kwong, Peter D., Casellas, Rafael·2021·Nature

Abstract

Since the start of the COVID-19 pandemic, SARS-CoV-2 has caused millions of deaths worldwide. Although a number of vaccines have been deployed, the continual evolution of the receptor-binding domain (RBD) of the virus has challenged their efficacy. In particular, the emerging variants B.1.1.7, B.1.351 and P.1 (first detected in the UK, South Africa and Brazil, respectively) have compromised the efficacy of sera from patients who have recovered from COVID-19 and immunotherapies that have received emergency use authorization 1–3 . One potential alternative to avert viral escape is the use of camelid VHHs (variable heavy chain domains of heavy chain antibody (also known as nanobodies)), which can recognize epitopes that are often inaccessible to conventional antibodies 4 . Here, we isolate anti-RBD nanobodies from llamas and from mice that we engineered to produce VHHs cloned from alpacas, dromedaries and Bactrian camels. We identified two groups of highly neutralizing nanobodies. Group 1 circumvents antigenic drift by recognizing an RBD region that is highly conserved in coronaviruses but rarely targeted by human antibodies. Group 2 is almost exclusively focused to the RBD–ACE2 interface and does not neutralize SARS-CoV-2 variants that carry E484K or N501Y substitutions. However, nanobodies in group 2 retain full neutralization activity against these variants when expressed as homotrimers, and—to our knowledge—rival the most potent antibodies against SARS-CoV-2 that have been produced to date. These findings suggest that multivalent nanobodies overcome SARS-CoV-2 mutations through two separate mechanisms: enhanced avidity for the ACE2-binding domain and recognition of conserved epitopes that are largely inaccessible to human antibodies. Therefore, although new SARS-CoV-2 mutants will continue to emerge, nanobodies represent promising tools to prevent COVID-19 mortality when vaccines are compromised.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-021-03676-z

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 232

Metadata

Authors
Xu, J., Xu, K., Jung, S., Conte, A., Lieberman, J., Muecksch, F., Lorenzi, J. C. C., Park, S., Schmidt, F., Wang, Z., Huang, Y., Luo, Y., Nair, M. S., Wang, P., Schulz, J. E., Tessarollo, L., Bylund, T., Chuang, G.-Y., Olia, A. S., Stephens, T., Teng, I.-T., Tsybovsky, Y., Zhou, T., Munster, V., Ho, D. D., Hatziioannou, T., Bieniasz, P. D., Nussenzweig, M. C., Kwong, P. D., & Casellas, R.
Venue
Nature
Published
2021-06-07
Volume
595
Issue
7866
Pages
278-282
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W3166262177
Cited by
232
References
17
FWCI
13.10
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. https://app.cochat.ai/papers/10.1038/s41586-021-03676-z
The paper
Xu, J., Xu, K., Jung, S., Conte, A., Lieberman, J., Muecksch, F., Lorenzi, J. C. C., Park, S., Schmidt, F., Wang, Z., Huang, Y., Luo, Y., Nair, M. S., Wang, P., Schulz, J. E., Tessarollo, L., Bylund, T., Chuang, G.-Y., Olia, A. S., . . . Casellas, R. (2021). Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature. https://doi.org/10.1038/s41586-021-03676-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.